» Articles » PMID: 30425571

Identification of Chemoresistance-associated MiRNAs in Breast Cancer

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2018 Nov 15
PMID 30425571
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neoadjuvant chemotherapy (NAC) is an effective therapeutic regimen for patients with breast cancer. However, some individuals cannot benefit from NAC because of drug resistance. To date, valid strategies about enhancing sensitivity of breast cancer to NAC are still scarce. miRNAs have been reported to proverbially be involved in the onset and development of malignancies including drug resistance.

Methods: GSE73736 was downloaded from the GEO database. Student's -test was conducted to acquire differentially expressed-miRNAs (DE-miRNAs). Potential target genes of DE-miRNAs were predicted by miRTarBase. Gene Ontology annotation and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses for these target genes were performed by database for annotation, visualization, and integrated discovery. Protein-protein interaction network was constructed by STRING database and visualized through Cytoscape software. The hub target gene-miRNA network was also established by Cytoscape software. Next, the expression of potential functional miRNAs in breast cancer cell lines and tissues was determined. Finally, the roles of miR-3617-3p, miR-3136-3p, and miR-520b in modulating breast cancer chemoresistance were further examined.

Results: A total of 123 DE-miRNAs were identified, including 60 upregulated miRNAs and 63 downregulated miRNAs in the chemoresistant breast cancer group when compared with the chemosensitive group. Six hundred and seventeen and 1,146 potential target genes for the top 10 most upregulated and downregulated miRNAs were predicted, respectively. Enrichment analyses revealed that these target genes were enriched in some cancer-associated or chemo-resistance-associated pathways, such as MAPK signaling pathway, wnt signaling pathway, and p53 signaling pathway. and were identified as hub genes in the protein-protein interaction network. The top 25 hub genes were potentially regulated by 16 DE-miRNAs, among which miR-3617-3p and miR-3136-3p were commonly upregulated, whereas miR-520b was downregulated in two chemoresistant breast cancer cells compared with chemosensitive cell. By analyzing TCGA data, we found that expression of miR-3136-3p and miR-520b was increased and decreased in breast cancer tissues, respectively. Moreover, functional experiments demonstrated that miR-3136-3p and miR-3617-3p could reduce chemosensitivity of breast cancer, whereas miR-520b could reverse chemoresistance.

Conclusion: The present study, based on bioinformatics analysis and experimental validation, brings to light novel mechanisms of breast cancer NAC resistance.

Citing Articles

Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review.

Yadav M, Vaishkiar I, Sharma A, Shukla A, Mohan A, Girdhar M Open Biol. 2024; 14(6):230272.

PMID: 38889771 PMC: 11285512. DOI: 10.1098/rsob.230272.


Robust Identification of Differential Gene Expression Patterns from Multiple Transcriptomics Datasets for Early Diagnosis, Prognosis, and Therapies for Breast Cancer.

Tuly K, Hossen M, Islam M, Kibria M, Alam M, Harun-Or-Roshid M Medicina (Kaunas). 2023; 59(10).

PMID: 37893423 PMC: 10608013. DOI: 10.3390/medicina59101705.


Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy.

Fan J, Tang Y, Wang K, Yang S, Ma B Breast Cancer (Dove Med Press). 2023; 15:591-604.

PMID: 37593370 PMC: 10427486. DOI: 10.2147/BCTT.S415080.


Comprehensive analysis of UBE2C expression and its potential roles and mechanisms in hepatocellular carcinoma.

Li X, Ma Z, Mei L Aging (Albany NY). 2023; 15(15):7397-7407.

PMID: 37580802 PMC: 10457065. DOI: 10.18632/aging.204792.


Genetic variations in tumor-suppressor miRNA-encoding genes and their target genes: focus on breast cancer development and possible therapeutic strategies.

Chhichholiya Y, Singh H, Singh S, Munshi A Clin Transl Oncol. 2023; 26(1):1-15.

PMID: 37093457 DOI: 10.1007/s12094-023-03176-8.


References
1.
Cui W, Zhang Y, Hu N, Shan C, Zhang S, Zhang W . miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3'UTR of CD46. Cancer Biol Ther. 2010; 10(3):232-41. DOI: 10.4161/cbt.10.3.12277. View

2.
Yang W, Li Y, Song X, Xu J, Xie J . Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing. Oncotarget. 2017; 8(16):26591-26599. PMC: 5432281. DOI: 10.18632/oncotarget.15721. View

3.
Zamanian Azodi M, Rezaei Tavirani M, Rezaei Tavirani M, Vafaee R, Rostami-Nejad M . Nasopharyngeal Carcinoma Protein Interaction Mapping Analysis via Proteomic Approaches. Asian Pac J Cancer Prev. 2018; 19(3):845-851. PMC: 5980865. DOI: 10.22034/APJCP.2018.19.3.845. View

4.
Liu M, Zhang Y, Zhang J, Cai H, Zhang C, Yang Z . MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A. Cell Death Dis. 2018; 9(2):189. PMC: 5833797. DOI: 10.1038/s41419-017-0218-x. View

5.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View